# US 2016/0237068 A1 · Hydrochloride salt form for ezh2 inhibition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237068 A1
- Document ID: US20160237068A1
- Status: Published application
- Kind: A1
- Application number: 15/029,848
- Filed: 2014-10-15
- Published: 2016-08-18
- Earliest claimed: 2013-10-16
- Assignees: Epizyme, Inc.; Eisai R&D Management Co., Ltd.
- Applicants: Epizyme, Inc.; Eisai R&D Management Co., Ltd.
- Inventors: Kevin W. KUNTZ; Hyeong-wook CHOI; Steven MATHIEU; Kristen SANDERS; Arani CHANDA
- Web page: https://patentgrep.com/patent/US20160237068A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.

## Claims

### Claim 1

Polymorph C of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide monohydrochloride.

### Claim 2 (depends on 1)

The polymorph according to claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having two or more characteristic peaks expressed in degrees 2-theta (+/−0.2) at 17.53, 18.66, 21.14, 22.22, 23.46, 27.72 and 30.30.

### Claim 3 (depends on 1)

The polymorph according to claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having three or more characteristic peaks expressed in degrees 2-theta (+/−0.2) at 17.53, 18.66, 21.14, 22.22, 23.46, 27.72 and 30.30.

### Claim 4 (depends on 1)

The polymorph according to claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having four or more characteristic peaks expressed in degrees 2-theta (+/−0.2) at 17.53, 18.66, 21.14, 22.22, 23.46, 27.72 and 30.30.

### Claim 5 (depends on 1)

The polymorph according to claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta (+/−0.2) at 17.53, 21.14, 23.46, and 27.72.

### Claim 6 (depends on 1)

The polymorph according to claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having at least eight characteristic peaks expressed in degrees 2-theta (+/−0.2), selected from the group consisting of 10.08, 10.94, 16.58, 17.12, 17.53, 18.34, 18.66, 20.50, 21.14, 21.92, 22.22, 23.46, 26.22, 26.60, 27.72, and 30.30.

### Claim 7 (depends on 1)

The polymorph according to claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having at least nine characteristic peaks expressed in degrees 2-theta (+/−0.2), selected from the group consisting of 10.08, 10.94, 16.58, 17.12, 17.53, 18.34, 18.66, 20.50, 21.14, 21.92, 22.22, 23.46, 26.22, 26.60, 27.72, and 30.30.

### Claim 8 (depends on 1)

The polymorph according to claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having at least ten characteristic peaks expressed in degrees 2-theta (+/−0.2), selected from the group consisting of 10.08, 10.94, 16.58, 17.12, 17.53, 18.34, 18.66, 20.50, 21.14, 21.92, 22.22, 23.46, 26.22, 26.60, 27.72, and 30.30.

### Claim 9 (depends on 1)

The polymorph of claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having peaks with 2-theta values substantially in accordance with FIG. 3.

### Claim 10 (depends on 1)

The polymorph of claim 1, wherein the polymorph exhibits an X-ray powder diffraction pattern having peaks with 2-theta values substantially in accordance with Table 3.

### Claim 11 (depends on 1)

The polymorph of claim 1, wherein the polymorph exhibits a differential scanning calorimetry thermogram showing a primary endotherm expressed in units of ° C. at a temperature of 228+/−5° C.

### Claim 12 (depends on 1)

The polymorph of claim 1, wherein the polymorph exhibits a differential scanning calorimetry thermogram substantially in accordance with the lowermost plot shown in FIG. 4.

### Claim 13 (depends on 1)

The polymorph of claim 1, wherein said polymorph is substantially free of impurities.

### Claim 14 (depends on 1)

The polymorph of claim 1, wherein said polymorph is a crystalline solid substantially free of amorphous N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)m ethyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1, 1′-biphenyl]-3-carboxamide monohydrochloride.

### Claim 15

A method of preparing Polymorph C of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide monohydrochloride, comprising the step of combining N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide with hydrochloric acid.

### Claim 16 (depends on 15)

The method of claim 15, comprising the steps of:
a) Dissolving N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide in a first solvent to obtain a solution;
b) Combining hydrochloric acid with the solution;
c) Combining a second solvent with the solution;
d) Precipitating or crystallizing Polymorph C of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide monohydrochloride from the solution; and
e) Collecting Polymorph C of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide monohydrochloride.

### Claim 17 (depends on 16)

The method of claim 16, wherein the first solvent comprises ethanol.

### Claim 18 (depends on 16)

The method of claim 16, wherein the hydrochloric acid is in a concentrated aqueous solution.

### Claim 19 (depends on 16)

The method of claim 16, wherein the second solvent comprises ethyl acetate.

### Claim 20 (depends on 16)

The method of claim 16, wherein one or more of the solutions of steps a), b) or c) is heated.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising a polymorph of claim 1, and a pharmaceutically acceptable carrier or diluent.

### Claim 22 (depends on 1, 21)

A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a polymorph of claim 1 or a pharmaceutical composition of claim 21.

### Claim 23 (depends on 22)

The method of claim 22, wherein the cancer is B cell lymphoma, non-Hodgkin's lymphoma or breast cancer.

### Claim 24 (depends on 1)

A method of inhibiting the histone methyltransferase activity of EZH2 in a subject in need thereof comprising administering to the subject an effective amount of a polymorph of claim 1.

### Claim 25 (depends on 1)

A method of inhibiting the histone methyltransferase activity of EZH2 in vitro comprising administering a polymorph of claim 1.

### Claim 26 (depends on 1)

A pharmaceutical composition comprising a polymorph of claim 1 for treating cancer.

### Claim 27 (depends on 26)

The pharmaceutical composition for treating cancer of claim 26, wherein the cancer is B cell lymphoma, non-Hodgkin's lymphoma or breast cancer.
